Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.19.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Total revenue $ 13,285 $ 3,395
Operating expenses:    
Research and development 30,202 9,487
General and administrative 14,082 11,755
Total operating expenses 44,284 21,242
Loss from operations 30,999 17,847
Interest and other income, net 751 51
Interest and other expense, net (990) (853)
Change in fair value of warrant liabilities 951 128
Loss on conversion of notes 0 (4,619)
Net loss 30,287 23,140
Deemed dividends on preferred stock 0 958
Net loss attributable to common shareholders $ 30,287 $ 24,098
Net loss per share attributable to common shareholders:    
Basic and diluted $ 1.02 $ 2.11
Weighted average number of shares used in net loss per share calculations:    
Basic and diluted 29,601,692 11,400,881
Net loss attributable to common shareholders $ 30,287 $ 24,098
Other comprehensive loss:    
Unrealized gain (loss) on available-for-sale securities 0 0
Comprehensive loss 30,287 24,098
Research And Development Revenue | Other    
Total revenue 196 500
Research And Development Revenue | Related Party    
Total revenue 7,087 1,908
Grant    
Total revenue $ 6,002 $ 987